Please login to the form below

Not currently logged in
Email:
Password:

Sanofi's Marcoux joins National Public Relations

He will lead the agency's healthcare communications practice

National PR, Christian Marcoux

Christian Marcoux has joined the Montreal office of National Public Relations as vice president of healthcare, where he will lead the agency's healthcare communications practice.

"Mr Marcoux's career began at National nearly 15 years ago," said managing partner, Serge Paquette.

"He has since taken on increasingly senior roles in the biopharmaceutical industry, at the local and global levels.

"He has solid experience in managing large multidisciplinary communications teams, and his background is rich and varied, ranging from financial communications to public relations, internal communications and studio productions.

"I'm convinced his arrival will not only benefit our clients with his sound counsel but it will also enhance our internal cross-office network."

Marcoux joins the agency from Sanofi, where he was associate vice president of global internal communications and studio production, at the pharma company's Paris headquarters.

Prior to this, he held senior communications positions with Pfizer, Canada and Merck Frosst Canada. He has also lectured on organisational communications at Université de Montréal.

Commenting on his appointment, Marcoux said: "My goal is that one day, people will see healthcare as an investment and not a commodity.

"I'm looking forward to helping people better understand the valuable role the healthcare industry plays in our society and the many great contributions it makes to our quality of life."

11th February 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...